After recently expanding operations into new countries including Oman, Lebanon, Venezuela, Bolivia and Kosovo, Beximco Pharmaceuticals announced growth of 7.5% in export sales to BDT697.2m ($8.22m) for its financial third quarter ended 31 March 2021. The company’s export sales grew by 2.4% to BDT2.09bn for the full first nine months of its financial year.
Beximco announced that it had begun exporting the antihistamine product cyproheptadine to the US market during its current financial year....